CYCC: כמות מזומנים למניה cyclacel.com

Cyclacel Pharmaceuticals focuses on developing CDK inhibitors to combat leukemia and solid tumors. The current cash per share level on the GURU.Markets chart confirms this stage, where the 1.91 level serves as a critical mark. Successful patent registration will ensure the company's market dominance, while a strong team of compliance and R&D experts guarantees the high-quality development of the therapy.
פילוחים אנליטיים של חברת Cyclacel Pharmaceuticals

This indicator determines the volume of liquid assets per common share, assessing the issuer's financial stability. An increase in this metric indicates the accumulation of reserves, while a decrease signals a risk of capital depletion. The annual trend of cash per share clearly demonstrates the balance between solvency and capital efficiency. For Cyclacel Pharmaceuticals (CYCC), this parameter is critical, as it secures the funding for the development of drugs targeting solid tumors. A sufficient cash reserve guarantees the continuation of clinical trials in the US and the UK.